Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2613-2619

  Drobnjak, Marija ^a   Melamed, Jonathan ^b   Taneja, Samir ^b   Melzer, Kate ^b   Wieczorek, Rosemary ^b   Levinson, Benjamin ^b   Zeleniuch Jacquotte, Anne ^b   Polsky, David ^b   Ferrara, Jay ^b   Perez Soler, Roman ^b   Cordon Cardo, Carlos ^a   Pagano, Michele ^b   Osman, Iman ^b,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEGRO; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RACE DIFFERENCE;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIBODIES, MONOCLONAL; CELL CYCLE PROTEINS; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPLASM; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECURRENCE; S-PHASE KINASE-ASSOCIATED PROTEINS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 12444339727     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Powell, I. J. Prostate cancer in the African American: is this a different disease? Semin. Urol. Oncol., 16: 221-226, 1998.
2. Powell, I. J., Banerjee, M., Novallo, M., Sakr, W., Grignon, D., Wood, D. P., and Pontes, J. E. Should the age specific prostate specific antigen cutoff for prostate biopsy be higher for black than for white men older than 50 years? J. Urol., 163: 146-148; discussion 148-149, 2000.
3. Powell, I. J., Banerjee, M., Sakr, W., Grignon, D., Wood. D. P., Jr., Novallo, M., and Pontes, E. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer (Phila.), 85: 472-477, 1999.
4. Myers, R. E., Hyslop, T., Wolf, T. A., Burgh, D., Kunkel, E. J., Oyesanmi, O. A., and Chodak, G. J. African-American men and intention to adhere to recommended follow-up for an abnormal prostate cancer early detection examination result. Urology, 55: 716-720, 2000.
5. Myers, R. E. African American men, prostate cancer early detection examination use, and informed decision-making. Semin. Oncol., 26: 375-381, 1999.
6. Powell, I. J., Banerjee, M., Novallo, M., Smith, D., and Pontes, J. E. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. Urology, 55: 246-251, 2000.
7. Powell, I. J., Heilbrun, L. K., Sakr, W., Grignon, D., Montie, J., Novallo, M., Smith, D., and Pontes, J. E. The predictive value of race as a clinical prognostic factor among patients with clinically localized prostate cancer: a multivariate analysis of positive surgical margins. Urology, 49: 726-731, 1997.
8. Grossfeld, G. D., Latini, D. M., Downs, T., Lubeck, D. P., Mehta, S. S., and Carroll, P. R. Is ethnicity an independent predictor of prostate cancer recurrence after radical prostatectomy? J. Urol. 168: 2510-2515, 2002.
9. Osman, I., Drobnjak, M., Fazzari, M., Ferrara, J., Scher, H. I., and Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res., 5: 2082-2088, 1999.
10. Osman, I., Scher, H. I., Drobnjak, M., Verbel, D., Morris, M., Agus, D., Ross, J. S., and Cordon-Cardo, C. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res., 7: 2643-2647, 2001.
11. Drobnjak, M., Osman, I., Scher, H. I., Fazzari, M., and Cordon-Cardo, C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin. Cancer Res., 6: 1891-1895, 2000.
12. Lee, C. T., Capodieci, P., Osman, I., Fazzari, M., Ferrara, J., Scher, H. I., and Cordon-Cardo C. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin. Cancer Res., 5: 977-983, 1999.
13. Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., Gaudin, P. B., Fazzari, M., Zhang, Z. F., Massague, J., and Scher, H. I. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J. Natl. Cancer Inst. (Bethesda), 90: 1284-1291, 1998.
14. Yang, R. M., Naitoh, J., Murphy, M., Wang, H. J., Phillipson, J., deKernion, J. B., Loda, M., and Reiter, R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J. Urol., 159: 941-945, 1998.
15. Cote, R. J., Shi, Y., Groshen, S., Feng, A. C., Cordon-Cardo, C., Skinner, D., and Lieskovosky, G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J. Natl. Cancer Inst. (Bethesda), 90: 916-920, 1998.
16. Erdamar, S., Yang, G., Harper, J. W., Lu, X., Kattan, M. W., Thompson, T. C., and Wheeler, T. M. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis. Mod. Pathol., 12: 751-755, 1999.
17. Cheville, J. C., Lloyd, R. V., Sebo, T. J., Cheng, L., Erickson, L., Bostwick, D. G., Lohse, C. M., and Wollan, P. Expression of p27kip1 in prostatic adenocarcinoma. Mod. Pathol., 11: 324-328, 1998.
18. Cheng, L., Lloyd, R. V., Weaver, A. L., Pisansky, T. M., Cheville, J. C., Ramnani, D. M., Leibovich, B. C., Blute, M. L., Zincke, H., and Bostwick, D. G. The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin. Cancer Res., 6: 1896-1899, 2000.
19. Hershko, D., Bornstein, G., Ben-Izhak, O., Carrano, A., Pagano, M., Krausz, M. M., and Hershko, A. Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer (Phila.), 91: 1745-1751, 2001.
20. Kudo, Y., Kitajima, S., Sato, S., Miyauchi, M., Ogawa, I., and Takata, T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res., 61: 7044-7047, 2001.
21. Latres, E., Chiarle, R., Schulman, B. A., Pavletich, N. P., Pellicer, A., Inghirami, G., and Pagano, M. Role of the F-box protein Skp2 in lymphomagenesis. Proc. Natl. Acad. Sci. USA, 98: 2515-2520, 2001.
22. Gstaiger, M., Jordan, R., Lim, M., Catzavelos, C., Mestan, J., Slingerland, J., and Krek, W. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl. Acad. Sci. USA, 98: 5043-5048, 2001.
23. Guo, Y., Sigman, D. B., Borkowski, A., and Kyprianou, N. Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients. Prostate, 42: 130-136, 2000.
24. Sarkar, F. H., Li, Y., Sakr, W. A., Grignon, D. J., Madan, S. S., Wood, D. P., Jr., and Adsay, V. Relationship of p21WAF1 expression with disease-free survival and biochemical recurrence in prostate adenocarcinomas (PCa). Prostate, 40: 256-260, 1999.
25. Platz, E. A., Rimm, E. B., Willett, W. C., Kantoff, P. W., and Giovannucci, E. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J. Natl. Cancer Inst. (Bethesda), 92: 2009-2017, 2000.
26. Gilligan, T. D., Halabi, S., Kantoff, P. W., Dawsoin, N. A., Kaplan, E. B., Small, E. J., and Vogelzang, N. J. African-American race is associated with longer survival in patients with metastatic hormone-refractory prostate cancer (HRCaP) in four randomized Phase III Cancer and Leukemia Group B (CALGB) trials. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 21: 725, 2002.
27. Osman, I., Sherman, E., Singh, B., Venkatraman. E., Zelefsky, M., Bosl, G., Scher, H., Shah, J., Shaha, A., Kraus, D., Cordon-Cardo, C., and Pfister, D. G. Inactivation of p53-pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J. Am. Soc. Clin. Oncol., 20: 2980-2987, 2002.
28. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M., and Pagano, M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.
29. Chiarle, R., Budel, L. M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., Maes, B., De Wolf-Peeters, C., and Inghirami, G. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95: 619-626, 2000.
30. Esposito, V., Baldi, A., De Luca, A., Groger, A. M., Loda, M., Giordano, G. G., Caputi, M., Baldi, F., Pagano, M., and Giordano, A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.
31. Piva, R., Cancelli, I., Cavalla, P., Bortolotto, S., Dominguez, J., Draetta, G. F., and Schiffer, D. Proteasome-dependent degradation of p27/kip1 in gliomas. J. Neuropathol. Exp. Neurol., 58: 691-696, 1999.
32. Carrano, A. C., Eytan, E., Hershko, A., and Pagano, M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1: 193-199, 1999.
33. Yang, G., Ayala, G., Marzo, A. D., Tian, W., Frolov, A., Wheeler, T. M., Thompson, T. C., and Harper, J. W. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin. Cancer Res., 11: 3419-3426, 2002.
34. Papandreou, C., Daliani, D., Millikanb, R., Tu, S., Pagliaro, L., Adams, J., Elliott, P., Nix, D., Dieringer, P., Thall, P., and Logothetis, C. J. Phase I Study of Intravenous (I. V.) Proteasome Inhibitor PS-341 in Patients (Pts) with advanced malignancies. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 340, 2001.
35. Logothetis, C. J., Yang, H., Daliani, D., Millikan, R. E., Tu, S., Pagliaro, L., Adams, J., Elliott, P., Nix, D., Dieringer, D., and Papandreou, C N. Dose-dependent inhibition of 20S proteasome results in serum IL-6 and PSA decline in patients (PTS) with androgen-independent prostate cancer (AI PCa) treated with the proteasome inhibitor PS-341. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 20: 740, 2001.
36. Hara, T., Kamura, T., Nakayama, K., Oshikawa, K., Hatakeyama, S., and Nakayama, K. Degradation of p27(Kip1) at the G(0)-G(1) transition mediated by a Skp2-independent ubiquitination pathway. J. Biol. Chem., 276: 48937-48943, 2001.
37. Carrano, A. C., and Pagano, M. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J. Cell Biol., 153: 1381-1390, 2001.
38. Signoretti, S., Dimarcotullio, L., Richardson, L., Ramaswamy, S., Isaac, B., Rue, M., Monti, F., Loda, M., and Pagano, M. Oncogenic roles of the ubiquitin ligase subunit Skp2 in human breast cancer. J. Clin. Oncol., 110: 633-4133, 2002.
39. Ganiatsas, S., Dow, R., Thompson, A., Schulman, B., and Germain, D. A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene, 20: 3641-3650, 2001.